Company intelligence / Profile preview

Marine Biomedical Research Institute of Qingdao

Ownership: Private
Development stage: Phase 1

Overview

Marine Biomedical Research Institute of Qingdao develops marine-derived small molecule drugs. Its lead asset BG-136 targets tubulin and is in Phase 1 clinical trials for solid tumors including colon cancer. Another preclinical candidate (MBRI-003) targets inflammatory bowel diseases. The institute collaborates with major pharma and local government to advance marine biomedicine innovation.

Therapeutic areas: OncologyGastroenterology
Modalities: Small molecule
Industry: Academic Hospital/University/Research

Drug pipeline

2 assets

BG136

Phase 1

Indications: Cancer

1 more asset in the full pipeline.

Request access →

Partnerships

Qingdao Guoxin GroupSino BiopharmCP Pharmaceutical Qingdao (for industry-academia-research collaboration)

Beyond the preview

Go deeper on Marine Biomedical Research Institute of Qingdao.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marine Biomedical Research Institute of Qingdao.

Explore the full profile